[
  {
    "ts": "2025-11-02T19:00:00+00:00",
    "headline": "Palantir, AMD, Pfizer, Robinhood, McDonald’s, and Many More Stocks to Watch This Week",
    "summary": "Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.",
    "url": "https://www.barrons.com/articles/palantir-amd-pfizer-robinhood-mcdonalds-stocks-dfd8631b?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "da279047-80a4-3f1c-b1cc-5987f743fabe",
      "content": {
        "id": "da279047-80a4-3f1c-b1cc-5987f743fabe",
        "contentType": "STORY",
        "title": "Palantir, AMD, Pfizer, Robinhood, McDonald’s, and Many More Stocks to Watch This Week",
        "description": "",
        "summary": "Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.",
        "pubDate": "2025-11-02T19:00:00Z",
        "displayTime": "2025-11-02T19:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/da279047-80a4-3f1c-b1cc-5987f743fabe/palantir-amd-pfizer-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a926b7a54bde2dc85c7fe0aa9b2a19b3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Izgadcjek.yBSILSef60dg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a926b7a54bde2dc85c7fe0aa9b2a19b3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bU4XIuvHkHT9MvI..HrHpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a926b7a54bde2dc85c7fe0aa9b2a19b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/palantir-amd-pfizer-robinhood-mcdonalds-stocks-dfd8631b?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "MCD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-02T10:30:00+00:00",
    "headline": "Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk",
    "summary": "Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.",
    "url": "https://www.wsj.com/health/pharma/why-pfizer-can-still-prevail-in-the-obesity-fight-with-novo-nordisk-3ecafe71?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "7ec7cc51-a791-3f8a-be28-4798d1214f28",
      "content": {
        "id": "7ec7cc51-a791-3f8a-be28-4798d1214f28",
        "contentType": "STORY",
        "title": "Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk",
        "description": "",
        "summary": "Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.",
        "pubDate": "2025-11-02T10:30:00Z",
        "displayTime": "2025-11-02T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7ec7cc51-a791-3f8a-be28-4798d1214f28/why-pfizer-can-still-prevail.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/535a3a05863083285fd2c72754076fa3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QZ2UQ7PXgpLUA19AZmSqow--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/535a3a05863083285fd2c72754076fa3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0M76YMyiIMP6OfaEW0yieA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/535a3a05863083285fd2c72754076fa3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/why-pfizer-can-still-prevail-in-the-obesity-fight-with-novo-nordisk-3ecafe71?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "AKRO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-02T09:20:00+00:00",
    "headline": "Is It Time to Dump Your Shares of Pfizer?",
    "summary": "Pfizer stock has dropped 50% over the past three years.",
    "url": "https://www.fool.com/investing/2025/11/02/is-it-time-to-dump-your-shares-of-pfizer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d0bf851a-5fdc-34cf-9637-36de2f43c4bc",
      "content": {
        "id": "d0bf851a-5fdc-34cf-9637-36de2f43c4bc",
        "contentType": "STORY",
        "title": "Is It Time to Dump Your Shares of Pfizer?",
        "description": "",
        "summary": "Pfizer stock has dropped 50% over the past three years.",
        "pubDate": "2025-11-02T09:20:00Z",
        "displayTime": "2025-11-02T09:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/321f411b82fe3315ace879ec47dcc672",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3lXZu_Hohd8hZ2af8FK68A--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/321f411b82fe3315ace879ec47dcc672.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kC4G.KKnG44Tdhx6FzpDBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/321f411b82fe3315ace879ec47dcc672.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/02/is-it-time-to-dump-your-shares-of-pfizer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-dump-shares-pfizer-092000669.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]